For consumers
(1300 633 424)
Mon-Fri | 9am-5pm AEST
Your call will be answered by healthdirect Australia
For health professionals
Find out the active ingredient and other brand names of your medicines with the NPS Medicine Name Finder
For a medicinewise Australia
Independent. Not-for-profit. Evidence based.
Published 2010-08-01 00:00:00
On 1 December 2010, anakinra (Kineret) will be deleted from the Schedule of Pharmaceutical Benefits. Anakinra will continue to be available as a private prescription.
Anakinra is currently a PBS authority listing for severe active rheumatoid arthritis. It is an interleukin-1 (IL-1) inhibitor and classified as a biological disease-modifying anti-rheumatic drug (bDMARD).
In December 2009, the Pharmaceutical Benefits Advisory Committee reviewed the clinical evidence for bDMARDs and their cost-effectiveness. The committee found that a significant price reduction was warranted for all bDMARDs listed on the PBS for rheumatoid arthritis.1 The sponsor of anakinra did not agree to the new price, and as a result it will be removed from the PBS.2
Abatacept (Orencia), adalimumab (Humira), etanercept (Enbrel), infliximab (Remicade), and rituximab (Mabthera) remain PBS listed for severe active rheumatoid arthritis. An additional three bDMARDs will be PBS subsidised for rheumatoid arthritis from 1 August 2010: certolizumab (Cimzia), golimumab (Simponi) and tocilizumab (Actemra).2 People receiving anakinra will need to see their specialist before 1 December 2010 to consider a transition to a PBS-subsidised treatment. From May 2009 to April 2010, 225 prescriptions and repeats for anakinra were reimbursed on the PBS, enough for ongoing supply for about 20 patients.3
Date published: 2010-08-01 00:00:00
Reasonable care is taken to provide accurate information at the date of creation. This information is not intended as a substitute for medical advice from a qualified health professional. Health professionals should rely on their own expertise and enquiries when providing medical advice or treatment. Where permitted by law, NPS disclaims all liability (including for negligence) for any loss, damage or injury resulting from reliance on or use of this information. Read our full disclaimer.
References to brands should not be taken as an endorsement by NPS.